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Abstract
Objectives. The aim was to investigate whether the signalling lymphocyte activation molecule (SLAM)
signalling pathways contribute to LN and whether SLAM receptors could be valuable biomarkers of dis-
ease activity.
Methods. Peripheral blood mononuclear cells from 30National Research Ethics Service SLE patients with
biopsy-proven LN were analysed by flow cytometry. Clinical measures of disease activity were assessed.
The expression of the SLAM family receptors on T-cell subpopulations [CD4, CD8 and double negative
(DN) T cells] was measured and compared between lupus patients with active renal disease and those in
remission.
Results. The frequency of CD8 T cells expressing SLAMF3, SLAMF5 and SLAMF7 was significantly lower
in LN patients who were in remission. In contrast, these subsets were similar in patients with active renal
disease and in healthy individuals. Patients with active nephritis had an increased percentage of circulat-
ing monocytes, consistent with a potential role played by these cells in glomerular inflammation. Changes
in the frequency of DN T cells positive for SLAMF2, SLAMF4 and SLAMF7 were observed in lupus patients
irrespective of the disease activity. We detected alterations in the cellular expression of the SLAM family
receptors, but these changes were less obvious and did not reveal any specific pattern. The percentage of
DN T cells expressing SLAMF6 could predict the clinical response to B-cell depletion in patients with LN.
Conclusion. Our study demonstrates altered expression of the SLAM family receptors in SLE T lympho-
cytes. This is consistent with the importance of the SLAM-associated pathways in lupus pathogenesis.
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Rheumatology key messages
. SLE patients with inactive nephritis have fewer CD8 T cells expressing SLAMF3, SLAMF5 or SLAMF7.
. SLAMF2-, SLAMF4- and SLAMF7-positive double negative T cells are differentially expressed in lupus patients.
. There is an increased proportion of SLAMF6 double negative T cells in LN patients non-responding to B-cell
depletion therapy.
Introduction
SLE is an autoimmune multisystem inflammatory disease
that is debilitating and can cause life-threatening organ
damage, such as LN. Patients with SLE develop patho-
genic autoantibodies that are directed towards a broad
range of ubiquitous self-antigens, including dsDNA and
nuclear debris from apoptotic cells. These immune
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complexes (ICs) deposit in organs, and the subsequent
influx of inflammatory cells contributes to widespread
tissue damage. Owing to its multifactorial aetiology, the
immunopathogenesis of SLE is extremely complex and
incompletely understood. However, it is widely accepted
that loss of B-cell tolerance, in conjunction with CD4 T-cell
hyperactivation, is central to lupus pathogenesis. In this
context, the signalling lymphocyte activation molecule
(SLAM) family receptors have recently emerged as key
players in the immune dysregulation underlying lupus
pathogenesis [1, 2]. Studies using knockout mice deficient
in SLAM family receptors and SLAM-associated protein
(SH2D1A) have shown that these molecules play an im-
portant role in T-cell-mediated help for humoral immunity
[3, 4] a key process in lupus pathogenesis.
The SLAM gene family comprises functionally related
cell-surface type I transmembrane receptors, which are
expressed broadly on haematopoietic cells, including T,
B and NK cells, myeloid and plasmacytoid dendritic cells,
macrophages and monocytes. Members of this family are
as follows: CD150 (SLAMF1), CD48 (SLAMF2), CD229
(SLAMF3, Ly-9), CD244 (SLAMF4, 2B4), CD84
(SLAMF5), NTB-A (SLAMF6) and CD319 (SLAMF7,
CRACC, CS1). With the exception of CD48, which inter-
acts with CD244, all of the SLAM members interact via
homophilic interactions. The SLAM receptors have immu-
noreceptor tyrosine-based switch motifs in their intracel-
lular domain that can be bound by SH2D1A and Ewing’s
sarcoma-activated transcript 2 (SH2D1B). These inter-
actions trigger important immunomodulatory effects [5, 6].
The SLAM gene cluster has been genetically associated
with SLE in humans and in murine models of SLE. In
humans, it is located within a chromosomal region,
1q23, that has been shown to have a strong linkage with
SLE in genome-wide association studies [7]. Likewise, the
syntenic linkage region on mouse chromosome 1 has
been shown to be a genetic susceptibility region for the
development of SLE in several spontaneous lupus-prone
models [8]. For example, polymorphisms in the Ly108
gene (corresponding to SLAMF6 in humans) result in the
generation of a Ly108 splice variant in lupus-prone mice
that is involved in the pathogenesis of SLE [9]. Thus,
emerging data provide strong arguments that these
genes play an important role in key processes believed
to lead to the development of SLE and therefore represent
strong functional candidates.
LN is one the most serious clinical manifestations of
SLE. It is a relapsing remitting GN that is treated with
CS and immunosuppressive medications, all with a con-
siderable side-effect burden for the patients. Thus, there
is growing recognition of the need to identify marker(s) of
disease flare/remission that will facilitate patient stratifica-
tion according to prognosis and treatment. We explored
whether expression of SLAM receptors on different T-cell
subpopulations [CD4, CD8 and double negative (DN)
T cells] could be used as a biomarker for LN. We analysed
SLE patients with active LN and those in remission but
with a history of LN. Unexpectedly, we found that patients
who were clinically inactive displayed more noticeable
changes in the expression of the SLAM gene family than
the healthy individuals. Taken together, our data provide
further support for the concept that SLAM molecules have
important disease-modifying effect(s) in SLE.
Methods
Patients
Thirty SLE patients (all of whom met the revised ACR cri-
teria [10] and the SLICC criteria [11]) with biopsy-proven LN
were recruited from the Imperial Lupus Centre (Table 1).
The LN subsets were categorized according to the
International Society of Nephrology/Renal Pathology
Society classification. Patients who had received CYC
and/or B-cell depletion within 6 months were excluded.
The BILAG index was used for clinical assessment and re-
sponse. Active LN was defined as urine protein:creatinine
ratio>50 mg/mmol together with biopsy-proven class III or
IV or V LN within 3 months of recruitment. Inactive LN was
defined as patients with a history of biopsy-proven LN and
on a prednisolone dose of410 mg daily together with renal
BILAG domain grade D, protein:creatinine ratio<20 mg/
mmol and no change in SLE-related medication within 12
months before recruitment. The healthy volunteer cohort
consisted of 4 males and 16 females, with a median age
of 34 years (range 2454 years). Samples from patients and
healthy volunteers were collected as a sub-collection regis-
tered with the Imperial College Healthcare Tissue Bank
(National Research Ethics Service approval 12/WA/0196).
Informed consent was obtained from all contributing indi-
viduals according to the Declaration of Helsinki. The Tissue
Management Committee of the Imperial College Healthcare
Tissue Bank approved the application (ref R13010a) to use
these samples in this study.
Ten out of the 19 active LN patients were treated with
rituximab (anti-CD20 antibody). The rituximab regimen
was two doses of rituximab (1 g) and methylprednisolone
(500 mg) on days 1 and 15 [12]. In two patients, methyl-
prednisolone was omitted because of concomitant oral
prednisolone. Owing to rituximab hypersensitivity, one pa-
tient received ofatumumab (a fully humanized anti-CD20
antibody). Background immunosuppressive medications
were continued if taken at baseline. Renal response to
B-cell depletion at 12 months was defined as follows: pro-
tein:creatinine ratio decrease by>50% from baseline,
estimated glomerular filtration rate560 ml/min or
if<60 ml/min at baseline, not fallen by>20% and im-
provement in overall disease activity scores (SLEDAI/
BILAG). Patients not meeting these criteria at 1 year
post B-cell depletion were defined as non-responders.
Non-responders included patients who required treatment
escalation.
Lymphocyte analysis by flow cytometry
Peripheral blood mononuclear cells, isolated from whole
blood by density gradient centrifugation, were stained
using the following panels: blood cell populations
(efluor450 anti-CD3, FITC anti-CD4, APC-efluor 780 anti-
CD8, PE-CY7 anti-CD19, PerCP-efluor 710 anti-CD14, PE
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anti-CD16 and APC anti-CD56); B-cell phenotype
(efluor450 anti-CD3, PE-CY7 anti-CD19, PE anti-CD24,
APC anti-CD27, FITC anti-CD38 and PerCP-efluor 710
anti-IgD); NK and NK T cells (APC or PE anti-CD56,
PerCP-efluor 710 anti-CD16, efluor-450 anti-CD3, PE
anti-Nkp30, PerCP-efluor 710 anti-Nkp44, APC anti-
Nkp46, PE-CY7 anti-abTCR and FITC anti-gdTCR); T-cell
phenotype [PE-CY7 anti-CD4, APC-efluor 780 anti-CD8,
V500 anti-CD3 (BD Biosciences, San Diego, CA, USA),
PerCP-efluor 710 anti-CCR7, FITC anti-CD45RA, efluor-
450 anti-CD45RO and PE anti-CXCR5]. SLAM receptor
expression on T cells was determined as follows: V500
anti-CD3, PE-CY7 anti-CD4, APC-efluor 780 anti-CD8,
PE anti-CD150, BV421 anti-CD48 (Biolegend, San
Diego, CA, USA), APC anti-CD229, FITC anti-CD244,
APC anti-CD84, PE anti-CD352 and PE anti-CD319.
Gate strategies are illustrated in supplementary Fig. S1,
available at Rheumatology Online. All antibodies were
obtained from e-Bioscience (San Diego, CA, USA)
unless noted differently. Non-specific Fc-mediated inter-
actions were blocked with human Fc receptor binding in-
hibitor. Flow cytometry was performed with a BD
FACSVerse (BD Biosciences). Data were analysed using
FlowJo software, version 10 (TreeStar, Ashland, OR,
USA).
Statistical analysis
Results were expressed as the mean (S.D.) or median
with interquartile range. Comparisons between two
groups were performed using the MannWhitney U-test,
between more than two groups using the analysis of
variance with Tukey’s multiple comparison test. A value
of P< 0.05 was considered statistically significant.
Statistical analysis was performed using GraphPad
TABLE 1 Baseline characteristics of study cohort



















1 III (A/C) MMF, HCQ 0 0 290 8 13/A 0 (0)
2 IV-S (A) MMF, HCQ, Pred 0 0 223 19 45/A 8 (7)
3 III (A) HCQ 0 0 289 13 23/A 0 (0)
4 V + III (A) MMF, HCQ, Pred 0 1 604 18 26/B 1 (1)
5 V + III (A/C) MMF, HCQ, Pred 0 0 77 8 17/B 1 (0)
6 V MMF, HCQ, Pred 0 1 270 8 8/B 8 (8)
7 V + III (C) MMF, HCQ 0 1 732 6 8/B 5 (4)
8 III (C) MMF, HCQ, Pred 3 1 91 8 8/B 12 (10)
9 V MMF, HCQ, Pred 6 1 134 12 13/A 30 (30)
10 V + III (A) MMF, HCQ 0 0 2010 7 34/A 0 (0)
11 IV-S (A/C) MMF, HCQ, Pred 0 0 161 13 31/B 6 (0)
12 III (A/C) HCQ, Pred, i.v.MP3 0 0 83 17 15/C 8 (0)
13 V + IV-S (A/C) AZA, Pred 6 1 1236 10 13/A 6 (5)
14 IV-G (A) MTX, HCQ, Pred, i.m.MP1 0 1 211 13 30/B 3 (3)
15 V + IV-G (A/C) MMF, Pred 3 0 272 8 12/A 17 (17)
16 V + IV-G (C) MMF, HCQ 0 1 398 4 12/A 7 (7)
17 IVG (C) HCQ, Pred 0 0 161 4 14/A 25 (24)
18 V MMF 3 0 294 8 12/A 17 (13)
19 III (A) MMF, HCQ 3 1 229 8 13/A 18 (12)
Inactive
20 IV AZA, Pred 0 0 <20 0 0/D 35 (35)
21 IV Pred 3 0 <20 0 0/D 28 (26)
22 V + III (C) MMF, HCQ 0 1 <20 0 0/D 29 (28)
23 V MMF 0 1 <20 0 0/D 11 (10)
24 III (A) AZA, HCQ 0 0 <20 4 0/D 15 (15)
25 III HCQ 0 0 <20 2 1/D 10 (10)
26 IV HCQ 3 1 <20 0 0/D 4 (4)
27 V AZA, HCQ 0 0 <20 2 1/D 30 (25)
28 III AZA, HCQ 0 1 <20 3 1/D 7 (7)
29 III None 0 1 <20 2 2/D 8 (8)
30 IV-G (A) AZA, HCQ 0 3 <20 6 2/D 11 (7)
CYC and RTX refer to treatments given at least 6 months before this study. LN duration was calculated from the time of the
first renal biopsy. aThe protein:creatinine ratio normal range is<20 mg/nmol. MP: methylprednisolone; Pred: prednisolone;
RTX: rituximab.
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Prism version 7.0 (GraphPad Software, San Diego, CA,
USA).
Results
Baseline clinical characteristics and cellular
phenotyping
A cohort of 30 biopsy-proven LN patients was evaluated.
Demographic features and baseline clinical scores are
shown in Table 1. The median age of the patients was
34.5 years, and the disease duration ranged from 0 to
35 years (8 years). Only three patients were males.
Among the 30 LN patients, 19 had active LN and 11 had
inactive LN. Median age and disease duration as well as
the distribution of sex and ethnic background were similar
in the active and inactive LN patients. The LN histological
classes were also equally distributed between the two
groups.
We initially assessed the distribution of the peripheral
blood subpopulations (Table 2). As expected, lupus pa-
tients displayed several cellular changes compared with
the healthy controls. The most notable differences
included a significant decrease in the frequency of NK
cells; in particular, of the CD56Dim NK fraction among
the NK cells; and a strikingly increased percentage of
naı̈ve B cells. These changes were independent of the
disease activity at the time of the analysis.
Patients with active LN had an increased frequency of
plasma cells, whereas the percentages of early memory
B cells, follicular and central memory CD4 T cells were
reduced compared with those in healthy donors. Of
note, an increased monocyte proportion was the only fea-
ture that distinguished active LN from both inactive LN
and controls (Table 1 and supplementary Fig. S2, avail-
able at Rheumatology Online). This relative increase is
likely to be the result of the more severe lymphopenia in
patients with active disease.
SLAM receptors on DN and CD8 T cells—potential
biomarkers of renal disease activity
Previous reports have shown that the SLAM gene family
may act as an important alternative pathway for T-cell co-
stimulation and that certain members are expressed ab-
normally in peripheral blood mononuclear cells from SLE
TABLE 2 Flow cytometry analysis of peripheral blood mononuclear cells
Cell population







HD(n = 19) (n = 11) (n = 21)
Total CD3 CD3+ 47.84 (16.87) 53.70 (16.17) 56.19 (10.22) 0.5303 0.1669 0.8872
CD4 CD3+ CD4+ 38.23 (20.50) 33.82 (18.40) 45.83 (14.55) 0.7909 0.3750 0.1757
Central memory
CD4
CD3+ CD4+ CD45RACCDR7+ 18.74 (9.36) 28.38 (5.99) 32.75 (13.90) 0.0915 0.0008* 0.5918
Effector CD4 CD3+ CD4+ CD45RO+ 8.24 (5.85) 1.72 (0.91) 7.22 (6.61) 0.0185* 0.8435 0.0514
Naı̈ve CD4 CD3+ CD4+ CD45RA+ CCDR7+ 29.73 (14.86) 39.34 (15.76) 26.51 (9.66) 0.1990 0.7235 0.0592
Follicular CD4 CD3+ CD4+ CXCR5+ 8.5 (4.60) 9.14 (4.47) 13.43 (4.97) 0.9321 0.0058* 0.0500*
CD8 CD8+ CD8+ 29.98 (17.01) 20.98 (14.66) 23.46 (11.17) 0.2350 0.3415 0.8910
Central memory
CD8
CD3+ CD8+ CD45RACCDR7+ 3.16 (5.21) 3.87 (1.45) 4.56 (4.94) 0.9237 0.6166 0.9277
Effector CD8 CD3+ CD8+ CD45RO+ 27.59 (13.42) 19.59 (17.63) 27.98 (14.11) 0.3705 0.9961 0.3307
Naı̈ve CD8 CD3+ CD8+ CD45RA+ CCDR7+ 37.92 (21.12) 56.92 (31.18) 31.49 (13.32) 0.0698 0.5977 0.009
DN CD3+ CD4CD8 5.75 (3.43) 3.68 (1.77) 5.25 (3.34) 0.1945 0.8688 0.3786
Ratio CD4/CD8 1.49 (0.74) 2.23 (1.77) 2.27 (1.04) 0.2173 0.0959 0.9945
NK CD3CD56+ 6.57 (3.26) 6.23 (4.84) 14.12 (7.94) 0.9873 0.0006* 0.0023*
CD56Dim NK CD3CD56Dim CD16Bright 59.05 (15.22) 58.05 (27.18) 88.7 (5.77) 0.9853 <0.0001* <0.0001*
CD56Bright NK CD3CD56Bright CD16Low 7.86 (4.95) 9.45 (11.04) 2.62 (2.63) 0.7810 0.0333* 0.0157*
NKT CD3+ CD56+ 1.51 (1.66) 1.17 (1.08) 2.85 (3.81) 0.9396 0.2754 0.2284
Total B CD3CD19+ 6.97 (7.23) 4.42 (1.73) 7.09 (11.42) 0.7123 0.9989 0.6850
Early memory B CD3CD19+ IgD+ CD27+ 3.37 (3.88) 8.57 (10.91) 17.19 (12.90) 0.3578 0.0002* 0.0634
Late memory B CD3CD19+ IgDCD27+ 17.67 (14.07) 20.57 (22.78) 35.36 (27.16) 0.9359 0.0407* 0.1838
Naı̈ve B CD3CD19+ IgD+ CD27 66.39 (21.78) 66.61 (34.92) 1.83 (1.73) 0.9996 <0.0001* <0.0001*
Plasma cells CD3CD19+ IgDCD27+ CD38+ 20.17 (19.26) 8.99 (9.10) 5.27 (4.78) 0.0700 0.0023* 0.7279
Transitional B CD3CD19+ IgDHigh CD27
CD38High CD24High
8.48 (7.10) 3.7 (5.14) 5.29 (3.99) 0.0725 0.1880 0.7301
Monocytes CD14+ 17.18 (8.75) 11.52 (3.59) 9.80 (3.13) 0.0422* 0.0011* 0.7285
Results are expressed as the mean (S.E.M.). The P-values were considered statistically significant when P< 0.05 according to
one-way analysis of variance with Tukey’s multiple comparison test. *Significant P-values. A: SLE patients with active LN;
DN: double negative T cells; HD: healthy donors; I: SLE patients with inactive LN; NKT: natural killer T cells; n: total number of
patients in the group.
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patients [1316]. To assess this in our patient cohort, we
analysed all SLAM receptors on the three main T-cell sub-
populations: CD4, CD8 and DN cells. Owing to technical
limitations, we aborted the assessment of SLAMF1 ex-
pression after the analysis of the first 12 patients. At this
stage, there were no differences between the three ex-
perimental groups (data not shown). The study of the re-
maining SLAM members, SLAMF2SLAMF7 inclusive, is
presented in Table 3, and the most informative findings
are shown in Fig. 1. The most prominent differences were
noted in the percentages of DN and CD8 T cells express-
ing SLAM receptors. The frequency of DN T cells positive
for SLAMF2, SLAMF4 or SLAMF7 was markedly altered in
SLE patients, but these differences were unrelated to the
disease activity. In contrast, the proportion of CD8 T cells
expressing SLAMF3, SLAMF5 or SLAMF7 was signifi-
cantly lower in the lupus patients in clinical remission
compared with the other two groups (Fig. 1A). A repeated
analysis using samples taken at a different time from a
small number of individuals showed consistent results,
demonstrating that the changes were stable (data not
shown). Differences in the expression of SLAMF2,
SLAMF3 or SLAMF4 were also noticed, but these
changes were less obvious and did not show a clear pat-
tern (Fig. 1B). Overall, in comparison with healthy controls,
the differences in expression were more marked in the
inactive rather than the active LN patients.
SLAMF6 expression as a potential predictor of the
clinical response of LN to B-cell depletion
During the course of the study, a subset of patients
(n = 11) with active LN received a B-cell depletion therapy.
As we had detected marked differences in the expression
of the SLAM receptors on T cells between SLE patients
and controls, we explored whether the SLAM cellular
phenotype was correlated with the clinical response to
B-cell depletion. The clinical features of this subset
cohort before B-cell depletion and at 12 months are
shown in Table 4. Five out of the 11 patients were classi-
fied as responders using the criteria described in the
Methods section. The remaining six patients required
CYC because of clinical deterioration. Having established
the pattern of response among the patients, we then as-
sessed whether the frequency of the SLAMF-positive DN
T cells could have predicted the clinical outcome at base-
line. Our data showed that the LN patients who failed to
achieve clinical remission had a higher frequency of
SLAMF6 DN T cells at baseline (P = 0.0303; Fig. 2).
Consistent with the notion that these non-responders
might have a more refractory renal disease, co-engage-
ment of SLAMF6 on DN T cells has previously been shown
to result in the production of greater amounts of pro-in-
flammatory cytokines, such as IFN-g and TNF-a, com-
pared with co-stimulation with anti-CD28 [13].
Discussion
The importance of the SLAM receptors in SLE derives
from their broad expression and their immunomodulatory
roles in the cross-talk between a number of immune cells
[6]. We focused our analysis on T-cell expression of SLAM
receptors in a cohort of SLE patients with biopsy-proven
nephritis categorized into those with active and those with
inactive LN. Our data showed that patients in clinical re-
mission have markedly reduced percentages of CD8 T
cells expressing SLAMF3, SLAMF5 or SLAMF7. This
may indicate decreased CD8 T-cell activation. In contrast,
changes in the frequency of the SLAMF2-, SLAMF4- and
SLAMF7-positive DN T cells, which share a gene expres-
sion profile with the CD8 T cells, distinguished the lupus
patients from healthy controls. However, these changes
were independent of nephritis activity. We also found a
higher proportion of CD352+ (SLAMF6) DN T cells in pa-
tients with active LN who subsequently failed to improve
with B-cell depletion therapy. The engagement of
SLAMF6 can prime T cells to produce Th1 cytokines, es-
pecially from CD8 and DN T cells [13]. We speculate that
the higher frequency of SLAMF6+ DN T cells, through
enhanced Th1 cytokine production, reflects a more ag-
gressive LN phenotype. If confirmed, this may have clin-
ical utility as a biomarker when deciding between B-cell
depletion therapy and CYC regimens. There is a need for
additional biomarkers beyond histological phenotyping,
because it is clear from our data (Table 4) and others
that the sub-type of LN is not correlated with treatment
response [17, 18].
Unsurprisingly, in our lupus cohort we observed several
cellular changes that mirror published findings. In agree-
ment with previous reports [19, 20], we found a higher
frequency of naı̈ve B cells, defined as CD19+
IgD+ CD27, in the SLE patients compared with healthy
controls. This increase was irrespective of the disease ac-
tivity, in keeping with the notion that even inactive SLE
patients fail to remove self-reactive naı̈ve B cells [21]. In
contrast, studies have reported that the CD27 naı̈ve B-
cell subpopulation is markedly reduced in the peripheral
blood of lupus patients [22, 23]. The heterogeneity of
CD27 B cells, previously thought to represent exclusively
naı̈ve B cells, has recently become apparent, and thus the
CD27 population may also contain memory B cells [24].
The use of these different markers makes it difficult to
compare studies. However, in the active SLE patients we
observed a reduction in the percentage of antigen-experi-
enced CD27+ memory B cells, a finding that is in conflict
with other studies [25]. Memory B cells are less susceptible
to immunosuppressive therapy because they are not
highly proliferative and conventional immunosuppressive
drugs depend on cell cycling. We speculate that our find-
ings may reflect the fact that many of our patients had a
long history of LN and had been treated with B-cell-deplet-
ing therapy. It might be that repetitive anti-CD20 treatment
cycles results in more substantial depletion of the memory
B-cell compartment compared with non-B-cell-depleting
immunosuppressive regimens. Independently, memory B
cells can easily differentiate into plasma cells because they
have lower activation thresholds. Consistent with this, we
found a significantly increased fraction of plasmablasts/
plasma cells in the SLE patients with active LN. This is in
agreement with reports showing strong correlations
1210 www.rheumatology.oxfordjournals.org














































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































SLAM receptors and LN
FIG. 1 Cellular analysis of signalling lymphocyte activation molecule receptors on T cells
Total T cells from 20 healthy donors and 19 active and 11 inactive LN patients were analysed for surface SLAM receptor
expression by flow cytometry. (A) Frequency of SLAM receptor-positive T cells. (B) Mean fluorescence intensity of SLAM
receptors. Bars represent median with interquartile range. P-values were determined by one-way analysis of variance
with Tukey’s multiple comparison test: *P< 0.05, **P< 0.005, ***P< 0.0005 and ****P< 0.0001. DN: double negative; MFI:
mean fluorescence intensity; SLAM: signalling lymphocyte activation molecule.
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between the frequencies of plasma cells and disease ac-
tivity [26] or the time of clinical relapse after B-cell-deplet-
ing therapies [27, 28]. Another striking difference between
the patients and the healthy controls was the marked re-
duction of the total NK cell frequency. Specifically, the
CD56Dim fraction, which is the most abundant one, was
reduced, whereas the CD56Bright was slightly increased.
Although numerical and functional defects in NK cells
have been described previously [2933], the NK cell lym-
phopenia seems to be a key feature of SLE patients with
renal involvement [34]. Whether this is the result of the
migration of the CD56Dim NK cells, a cell type with high
cytotoxic capacity, into the inflamed kidney can only be
speculated without further studies at the site of tissue
damage.
Several studies have explored the expression of the
SLAM receptors on immune cells from SLE patients, but
the results are variable. This is likely to reflect the hetero-
geneity of SLE. To address this, we chose to study SLE
patients with biopsy-proven LN. Our cohort was well char-
acterized and our definitions of active and inactive LN were
rigorous to enable us to explore reliably whether LN dis-
ease activity and the response of LN to B-cell depletion
were associated with differential expression of T-cell
SLAM genes. The SLAM receptors are important alterna-
tive pathways of T-cell co-stimulation. Consequently, it is
not surprising that we found several abnormalities in SLE T
cells. However, the most striking abnormalities were de-
tected in the CD8 and DN T cells rather than CD4 T cells.
CD8 and DN T cells are closely linked populations,
because at least some of the DN cells may represent
CD8 subsets that have lost CD8 from the surface mem-
brane [35, 36]. Although the DN T-cell population was not


































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































FIG. 2 Frequency of double negative T cells expressing
SLAMF6 at baseline
Comparison of the percentage of SLAMF6-positive DN T
cells between responders and non-responders. Response
to B-cell depletion was determined at 12 months post-
infusion. P-values were determined by the MannWhitney
U-test: *P = 0.0303. DN: double negative; SLAM: signalling
lymphocyte activation molecule.
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SLAMF4- and SLAMF7-expressing cells were significantly
different in the lupus patients, regardless of the disease
activity, compared with the healthy controls. Consistent
with our observation a study by Kis-Toth et al. [14]
showed that SLE patients had significantly fewer
SLAMF4-expressing CD8 T cells compared with healthy
controls and that these cells were functionally impaired.
Interestingly, these cells had an increased propensity to
lose CD8 and to become DN T cells, spontaneously as
well as upon activation. Furthermore, a reduced proportion
of NK cells and monocytes positive for SLAMF4 was
reported by Kim et al. [16], and a single nucleotide
polymorphism of SLAMF4 has been associated with the
presence of renal and neuropsychiatric manifestations in
SLE patients [37]. SLAMF4 is known to interact with high
affinity with SLAMF2 (CD48), and this interaction can me-
diate both activating and inhibitory pathways, depending
on the cell type and the experimental conditions. It is thus
intriguing that we found an increased proportion of
SLAMF2-expressing DN T cells in the SLE patients, a find-
ing that may indicate a compensatory mechanism.
Our study also revealed a striking loss of CD8 T cells
expressing SLAMF3, SLAMF5 or SLAMF7 in the lupus pa-
tients in clinical remission. In keeping with the recent
notion that an exhausted CD8 T-cell signature may predict
good clinical outcome [38, 39], these changes may repre-
sent an exhausted cellular distribution. Previous studies
on the expression and role of SLAMF3, SLAMF5 and
SLAMF7 in SLE have focused on CD4 T cells, plasmacy-
toid dendritic cells or NK cells and highlighted how the li-
gation of these receptors may promote prolonged
inflammation and tissue damage [15, 40]. Interestingly, it
has been shown that plasmacytoid dendritic cells from
SLE patients have lower expression of SLAMF5 and
SLAMF7, whereas SLAMF3 is decreased on CD56dim
NK cells. More importantly, their expression was found
to be upregulated by RNA-containing ICs, and these
may trigger increased IFN-a secretion, promoting disease
development [15]. Therefore, it is tempting to speculate
that the lower frequency of SLAMF3-, SLAMF5- and
SLAMF7-positive CD8 T cells in clinically inactive patients
may reflect the reduced activation by pathogenic RNA-
containing ICs. At the same time, these changes might
decrease the activation threshold of these cells, acting
as a negative feedback mechanism that helps to maintain
the clinical remission. Further studies on the precise func-
tion of these SLAM receptors on CD8 T cells will be
required to prove this formally.
The efficacy of B-depleting therapies in SLE remains
controversial, with contradictory results from open-label
and randomized controlled trials [4144]. Even in studies
that have demonstrated a benefit from treatment with
rituximab, there has been considerable variability in initial
response and time to relapse. We therefore explored
whether the cellular expression of the SLAM family recep-
tors could be a valuable predictive marker of renal
response to B-cell depletion and help to apply B-cell-
depleting agents more effectively. By monitoring the re-
sponse at 1 year in a small cohort of LN patients, we found
that patients with more circulating SLAMF6-expressing
DN T cells before treatment failed to respond to B-cell
depletion and required additional immunosuppressive
therapy. In our study, as in a previous report [13], the ex-
pression of SLAMF6 on the surface of the T-cell subpo-
pulations analysed was comparable between the SLE T
cells and the normal T cells. However, the proportion of
SLAMF6-expressing CD4 T cells was higher in the active
lupus patients compared with the patients in remission.
Interestingly, the SLAMF6-driven co-stimulation has
been shown to be defective in SLE T cells. The defect
was more pronounced in CD8 and DN T cells that also
appear to produce more cytokines following engagement
of SLAMF6 [13, 40]. Although it is tempting to propose
that the frequency of SLAMF6+ DN T cells could help to
identify LN patients requiring aggressive immunosuppres-
sive regimens, such as CYC, it is also important to recog-
nize that our finding could be relevant for only a small
group of patients and thus have a limited value in clinical
practice. Future studies in other LN cohorts are needed to
validate the use of SLAMF6 on DN T cells as a predictive
biomarker of response to B-cell depletion.
In summary, by analysing a selective group cohort of
SLE patients with biopsy-proven LN we discovered sev-
eral abnormalities in the SLAM family receptors on T
lymphocytes. We identified a selective loss of CD8 T
cells expressing SLAMF3, SLAMF5 or SLAMF7 in the
lupus patients in clinical remission. In addition, we have
shown that SLAMF6 on DN T cells could be a useful
marker for assessing the response to B-cell depletion
therapy. Overall, our study provides further support to
the notion that the SLAM gene family plays a crucial role
in lupus pathogenesis.
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